Azidothymidine Another Name for Zidovudine Facts

Introduction

Azidothymidine, also known as zidovudine or AZT, is a significant antiretroviral medication used to treat and prevent HIV/AIDS. As the first approved drug for this purpose, azidothymidine has played a crucial role in managing the HIV epidemic since its introduction in 1987. This article provides a comprehensive overview of azidothymidine, including its history, chemical composition, mechanism of action, uses, side effects, and impact on public health.

Historical Background

Azidothymidine was first synthesized in 1964 as a potential cancer treatment, but its antiviral properties were not discovered until the 1980s. In 1985, scientists at the National Cancer Institute identified AZT as a promising compound for inhibiting the replication of HIV [1]. After successful clinical trials, azidothymidine was approved by the FDA in 1987, making it the first antiretroviral drug available for treating HIV/AIDS [2].

Chemical Composition

Azidothymidine is a pyrimidine 2′,3′-dideoxyribonucleoside with the chemical formula C10H13N5O4. It is structurally similar to the naturally occurring nucleoside thymidine, but with an azido group replacing the hydroxyl group at the 3′ position of the sugar moiety Zidovudine” target=”_blank”>[3].

Mechanism of Action

As a nucleoside reverse transcriptase inhibitor (NRTI), azidothymidine works by inhibiting the activity of HIV reverse transcriptase, an enzyme essential for viral replication. AZT is incorporated into the growing viral DNA chain, leading to chain termination and preventing further elongation. This mechanism effectively reduces the production of new HIV particles and slows the progression of the infection [4].

Uses

Azidothymidine is primarily used for the treatment of HIV/AIDS in combination with other antiretroviral medications. It is also used to prevent mother-to-child transmission of HIV during pregnancy and childbirth. AZT is available in various forms, including the brand names Retrovir, Combivir (in combination with lamivudine), and Trizivir (in combination with lamivudine and abacavir) [5].

Dosage and Administration

The recommended dosage of azidothymidine for adults is 300 mg twice daily, taken orally with or without food. For pediatric patients, the dosage is based on body weight and is typically 180 mg/m2 every 6 hours. AZT is also available in intravenous form for patients unable to take oral medications [6].

Brand Names and Synonyms

Azidothymidine is marketed under various brand names, including Retrovir, Combivir, and Trizivir. Other common synonyms for azidothymidine include AZT, ZDV, Novo-Azt, and Aztec.

Clinical Trials and Research

Numerous clinical trials have demonstrated the efficacy of azidothymidine in treating and preventing HIV/AIDS. The landmark BW 002 study, published in 1987, showed that AZT significantly reduced mortality and opportunistic infections in patients with advanced HIV [7]. Subsequent trials, such as ACTG 076, established the role of AZT in preventing mother-to-child transmission of HIV [8]. Ongoing research continues to investigate the use of AZT in combination with other antiretroviral drugs and its potential applications in other areas of medicine.

Side Effects and Warnings

Common side effects of azidothymidine include headache, nausea, and loss of appetite. More serious adverse effects, such as hematologic toxicity and mitochondrial toxicity, may occur with long-term use. Patients with a history of bone marrow suppression or liver disease should use AZT with caution. Pregnant women should be advised of the potential risks and benefits of using AZT during pregnancy [9].

Drug Interactions

Azidothymidine may interact with other antiretroviral drugs, such as stavudine and ribavirin, leading to increased toxicity. It can also interact with various non-HIV medications, including aspirin, codeine, and methadone. Patients should inform their healthcare providers about all medications they are taking before starting AZT therapy [10].

Pharmacokinetics

Azidothymidine is rapidly absorbed from the gastrointestinal tract, with peak plasma concentrations occurring within 0.5 to 1.5 hours after oral administration. It is widely distributed throughout the body, including the central nervous system, and undergoes hepatic metabolism. The elimination half-life of AZT is approximately 1 hour, and it is primarily excreted in the urine as metabolites [11].

Regulatory Status

Azidothymidine was first approved by the FDA in 1987 for the treatment of HIV/AIDS. Since then, it has received approval for additional indications, such as the prevention of mother-to-child transmission of HIV. AZT is also approved for use in many other countries worldwide and is included in the World Health Organization‘s List of Essential Medicines [12].

Resistance

HIV can develop resistance to azidothymidine through mutations in the reverse transcriptase gene, leading to reduced efficacy of the drug. Resistance is more likely to occur when AZT is used as monotherapy or when patients have poor adherence to their medication regimen. Combination therapy with other antiretroviral drugs can help prevent the development of resistance [13].

Patient Information

Patients taking azidothymidine should be advised to take the medication exactly as prescribed and to report any side effects to their healthcare provider. They should also be informed about the importance of adherence to their medication regimen and the potential for drug interactions. Patients should undergo regular monitoring for adverse effects, such as hematologic toxicity, and should be advised to practice safe sex and avoid breastfeeding to prevent the transmission of HIV [14].

Public Health Impact

The introduction of azidothymidine as the first antiretroviral drug for HIV/AIDS has had a profound impact on the global HIV epidemic. AZT has contributed to significant reductions in mortality rates, improved quality of life for people living with HIV, and helped prevent the transmission of HIV from mother to child. However, challenges remain in ensuring access to AZT and other antiretroviral drugs in low- and middle-income countries [15].

Ethical and Access Issues

The development and distribution of azidothymidine have raised various ethical and access issues. In the early years of the HIV/AIDS epidemic, the high cost of AZT and limited availability of the drug led to disparities in access to treatment. Efforts to improve access to antiretroviral therapy in resource-limited settings have been ongoing, but significant gaps remain [16].

Future Directions

Despite the success of azidothymidine in treating and preventing HIV/AIDS, there is still a need for new and improved antiretroviral therapies. Ongoing research aims to develop drugs with better safety profiles, reduced pill burden, and increased efficacy against drug-resistant strains of HIV. Additionally, efforts to improve access to antiretroviral therapy and support adherence to treatment regimens remain crucial in the global fight against HIV/AIDS [17].